Voyager Therapeutics, Inc.
VYGRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeVoyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company carries a $189.7M market cap, placing it firmly in the micro-cap category. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Market Cap
$189.7M
Beta
1.27
P/E (TTM)
—
P/E (Fwd)
-2.01
EPS (TTM)
$-2.03
EPS (Fwd)
$-1.56
ROE
-52.3%
ROA
-27.1%
Cash
$141.5M
Total Debt
$34.6M
Free CF
-$80.8M
52W Change
-0.6%
Annual Financials
Cash vs Debt
Where VYGR stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, VYGR finished 18.77% below its 150-day moving average ($3.89) and 21.78% below its 200-day moving average ($4.04). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VYGR overbought or oversold?
At the July 15, 2026 close, VYGR's RSI(14) was 32.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $141.5M in cash and $34.6M in debt, VYGR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$80.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -52.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $40.9M (2022) to $40.4M (2025).
With cash comfortably exceeding debt, VYGR has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Voyager Therapeutics, Inc. and its sector.